7 results
Early Events in Acute GVHD #Pathophys #Honc #GVHD #GraftVersusHostDisease #NEJM
Events in Acute GVHD ... #Pathophys #Honc ... #GVHD #GraftVersusHostDisease ... #NEJM
Biologic Events Leading to Chronic GVHD #Pathophys #Honc #Pharm #GVHD #GraftVersusHostDisease #Therapeutic #Pathways #NEJM
Leading to Chronic GVHD ... #Pathophys #Honc ... #Pharm #GVHD #GraftVersusHostDisease ... Therapeutic #Pathways #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Non–Small-Cell Lung Cancer #EBM ... #Honc #Alectinib ... #Crizotinib #ALK ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival #EBM ... #Honc #Osimertinib ... #NSCLC #Survival ... #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM
Diagnostic Algorithm for Non–Small-Cell Lung Cancer (NSCLC). The upper portion of the algorithm shows the morphologic
classification of NSCLC ... mutations and ALK ... #Diagnosis #Honc ... #Algorithm #NSCLC ... #PDL1 #NEJM
The Mechanism of Small Interfering RNA (siRNA) Therapy. Synthetic double-stranded RNA containing an ALAS1-specific sequence is
level of delta ALA ... production of ALA ... #Pathophys #Honc ... siRNA #Therapy #NEJM